Remove 2023 Remove Clinic Remove Disease Remove Radiopharmaceuticals
article thumbnail

Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

Imaging Technology

milla1cf Tue, 10/17/2023 - 13:07 October 17, 2023 — Radionetics Oncology, Inc., Adrenocortical carcinoma is a disease with a desperate need for new agents, as the last drug approved by the FDA was in 1970. Despite significant research efforts, the median survival of patients with metastatic disease is less than 15 months.

article thumbnail

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Imaging Technology

milla1cf Wed, 12/06/2023 - 18:20 December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., Under the agreement, the Philogen Group is conducting a Phase 1 clinical study to evaluate the safety and dosimetry of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) in patients with solid tumors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

article thumbnail

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 for use in radiopharmaceutical therapy (RPT).

Medical 98
article thumbnail

MIM Software Receives FDA Clearance for Theranostics Portfolio

Imaging Technology

As Theranostics and the use of radiopharmaceutical therapy (RPT) to treat cancer and other diseases have become more prevalent, interest in using dosimetry to personalize RPT treatments has grown. Dosimetry in Radiopharmaceutical Therapy. 2023 May 22;68(11). J Nucl Med. 2022 Oct;63(10):1467-1474. doi: 10.2967/jnumed.121.262305.

article thumbnail

World’s First Cancer Patient Treated with RefleXion’s Breakthrough SCINTIX Biology-guided Radiotherapy

Imaging Technology

milla1cf Wed, 08/23/2023 - 19:19 August 23, 2023 — RefleXion Medical , a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX biology-guided radiotherapy on the RefleXion X1 machine at the Stanford Medicine Cancer Center. founder and CTO of RefleXion.“We

article thumbnail

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

Food and Drug Administration (FDA) on May 25, 2023. We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. POSLUMA was approved by the U.S. Chief Executive Officer of the Company. “We Teoh, MBBS, MRCP, FRCR, D.Phil.,